In a randomized , double-blind , placebo - and active-controlled Phase 3 trial conducted in Europe and Australia ( NCT00689104 ) , mirabegron 50mg and 100mg resulted in statistically significant reductions from baseline to final visit , compared with placebo , in the co-primary end points - mean number of incontinence episodes/24h and mean number of micturitions/24h .
